HRS-3738
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 06, 2026
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=74 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | N=198 ➔ 74 | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Oct 2024 ➔ Dec 2026
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
July 29, 2022
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=198 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
May 06, 2022
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=198 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology
1 to 3
Of
3
Go to page
1